Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK HTA (health technology assessment) body unimpressed by clinically-effective but "expensive" Exubera inhaled insulin from Pfizer

This article was originally published in Clinica

Executive Summary

Inhaled insulin was today given a provisional thumbs down in the ongoing appraisal of its potential use to treat type 1 and 2 diabetes in the UK's National Health Service, on the basis of its cost. The health technology assessment (HTA) conducted for the National Institute for Health and Clinical Excellence (NICE) is based on a review of Exubera, manufactured by Pfizer. The delivery device is produced by Bespak in the UK and West Pharmaceuticals in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel